dennis mccain
  • Home
  • Investing
    • Dividend Kings
    • Div Aristocrats
    • Div Champions
    • Business Dev Cos
    • Monthly Dividends
  • Options
    • Weekly Options

Investing

Ideas and Strategies on Investing.

Previous Articles

Pfizer

12/14/2016

0 Comments

 
Pfizer Inc. is an American global pharmaceutical corporation headquartered in New York City, with research headquarters in Groton, Connecticut. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer's products include the blockbuster drug Lipitor, used to lower LDL blood cholesterol; Lyrica for neuropathic pain/fibromyalgia; Diflucan, an oral antifungal medication; Zithromax, an antibiotic; Viagra for erectile dysfunction; and Celebrex/Celebra, an anti-inflammatory drug.
​
Picture
Pfizer Inc (PFE) declares a $0.32/share quarterly dividend which is a 6.7% increase from its prior dividend of $0.30. The forward yield is now 3.94% and payable March 1, for shareholders of record on Feb. 3. The ex-dividend date is Feb. 1.

​Pfizer Inc.
discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, and Transgene S.A.; and a research and development agreement with the National Cancer Institute to conduct clinical trials to evaluate investigational immunotherapy agents. The company has a partnership with The University of Pittsburgh to develop a computational model to identify the drivers of schizophrenia, Alzheimer's disease, and related brain diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
(Summary) (Company) (Chart)
12 December 2016
Price $32.40
1yr Target $37.85
Analysts 20
Dividend $1.20
Payout Ratio 120.00%

1yr Cap Gain 16.82%
Yield 3.70%
1yr Tot Return 20.52%

P/E 32.34
PEG 4.87
Beta 0.89


EPS (ttm) $1.00
EPS next yr $2.63
Forward P/E 12.34
EPS next 5yr 6.63%
1yr Price Support $17.43

Market Cap $196.54 Bil
Revenues $53.24 Bil
Earnings $6.18 Bil
Profit Margin 11.60%

Quick Ratio 0.90
Current Ratio 1.10
Debt/Equity 0.70


1yr RevGR -1.53%
3yr RevGR -3.63%
5yr RevGR -5.61%

1yr EarnGR -21.84%
3yr EarnGR -16.83%
5yr EarnGR 1.70%

1yr DivGR 7.54%
3yr DivGR 8.11%
5yr DivGR 9.02%

ROA 3.60%
ROE 9.70%


My Opinion

With Pfizer's recent dividend increase, the annual dividend is now back to where it was 2008. That's not a great consolation for those investors who have held the stock through the years, but it is cause for reconsideration of an investment in the company. Management is obviously trying to turn around a huge company and looking at the fundamentals, they may finally be getting somewhere. The recent dividend increase, as well as the previous 7 dividend increases, in indicative of a management team that has confidence in the future of the company. As an investor in large cap stocks, a great management team means a lot.  

That said, for me its time to consider initiating a position in the company. I would love to buy these shares at $30 per share but I think that ship has sailed. Over the last year investors have had a couple of chances to buy these at that level but that may not happen again, especially since they just raised their dividend. So I think at today's price I consider this to be an acceptable price for me to pay.

I expect to start with a small position, add to that position on any pullback, sell options on any position I obtain, and institute a dividend reinvestment strategy for additional shares. As long as the stock price continues higher and the dividends are increased annually, I'll keep holding these shares as well as add to that position.
 
Picture
PFE Monthly Chart
Picture
PFE Dividend History
Picture
0 Comments



Leave a Reply.

    Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

    Picture

    Author

    I am an Individual Investor with specific interest in long term growth and then enhancing my returns with income from dividends and derivatives. I don't recommend stocks to anyone (it's a good way to lose friends) and no one reading this should misinterpret my blog as a recommendation for any type of investment. I am writing this solely for myself and my kids.


    RSS Feed


    Picture
    Top 100 Blogs for Dividend Investors

    Picture
    Follow Me on StockTwits!



    Dividend Growth Stocks
    Dividend Growth Investor


    Picture
    I'm on Seeking Alpha too!

    Archives

    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013


    ADDITIONAL RESOURCES:
    4 Month INDU Chart
    Dividend Ex-Dates
    Bidness Etc
    SharpCharts Voyeur
    StockCharts.com

    FINVIZ
    Seeking Alpha
    BDC Reporter
    Roadmap2Retire
    DivHut
    Dividend Growth Investor

    Dividend Yield

    Stock Market Mentor
    Chart Swing Trader
    Dividend Announcements
    IBD TV
    Stocks to Watch Today
    Dividend Detective

    DISCLAIMER
     I am not a licensed investment adviser, and I am not providing investment advise for you on this site. Please consult with an investment professional before you invest your money. Any opinion expressed here should not be treated as investment advice. I am not liable for any losses suffered by any party because of data or information published on this blog. Past performance is not a guarantee of future performance. Unless your investments are FDIC insured, they may decline in value.

    Picture
Powered by Create your own unique website with customizable templates.